[Spring, Health Guardian] R&D Strength That Secured Approval in Demanding Advanced Countries

Daewoong Pharmaceutical Research and Development Achievements

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical officially launched its botulinum toxin product, developed through independent research and development (R&D), in the United States?the world's largest botulinum toxin market?in May last year under the name 'Juvo'. In September last year, it obtained marketing approval in Europe, and in October, it was launched in Canada under the name 'Nusiba'. The background behind acquiring approval from the notoriously stringent advanced country regulatory agencies and confidently entering the global market lies in Daewoong Pharmaceutical's differentiated R&D capabilities.

Under the vision of "improving the quality of human life through the development of treatments for intractable diseases," Daewoong Pharmaceutical is dedicating its R&D efforts to developing the 'Next Nabota'. This year, the company possesses its most impressive new drug pipeline since its founding, and it is expected to be a year in which the results of new drug development will be actively produced.

The product expected to show visible results first is the next-generation gastroesophageal reflux disease treatment 'Pexuprazan'. The company has already completed the application for product approval with the Ministry of Food and Drug Safety for the indication of 'erosive gastroesophageal reflux disease'. The goal is to enter clinical trials in the United States and China within this year, and it is drawing a roadmap to enter the global market, which is estimated to be worth about 40 trillion KRW.

Daewoong Pharmaceutical's SGLT-2 inhibitor 'DWP16001', being developed as a treatment for type 2 diabetes, has advantages in superior efficacy and duration of effect compared to existing marketed drugs. Currently, phase 2 clinical trials are underway domestically, and if development succeeds, it will be the first domestic pharmaceutical company to launch a new SGLT-2 inhibitor diabetes drug.

This content was produced with the assistance of AI translation services.